453-34-9

Usage

Uses

Used in Pharmaceutical Synthesis:
4,4,4-Trifluoro-3-hydroxybutyramide is used as an intermediate for the synthesis of pharmaceuticals, leveraging its trifluoro and hydroxy groups to create fluorinated pharmaceuticals and other biologically active molecules. Its unique structure allows for the development of new drugs with improved properties.
Used in Agrochemical Production:
In the agrochemical industry, 4,4,4-trifluoro-3-hydroxybutyramide serves as an intermediate, contributing to the creation of effective and novel agrochemicals that can enhance crop protection and yield.
Used as a Reagent in Organic Synthesis:
4,4,4-Trifluoro-3-hydroxybutyramide is utilized as a reagent in organic synthesis, where its specific functional groups facilitate targeted chemical reactions, leading to the formation of desired organic compounds.
Used in the Production of Fluorinated Compounds:
As a building block, 4,4,4-trifluoro-3-hydroxybutyramide is instrumental in the production of various fluorinated compounds, which are known for their diverse applications in different industries, including pharmaceuticals, materials science, and agrochemicals.
Used in Medicinal Chemistry and Drug Discovery:
4,4,4-Trifluoro-3-hydroxybutyramide holds potential in the field of medicinal chemistry and drug discovery, where its unique properties can be harnessed to design and develop new therapeutic agents with enhanced efficacy and selectivity.

InChI:InChI=1/C4H6F3NO2/c5-4(6,7)2(9)1-3(8)10/h2,9H,1H2,(H2,8,10)

Upstream product

• 372-30-5 ethyl 3-hydroxy-4,4,4-trifluorobutyrate 

Downstream Products

• 431-38-9 3-amino-1,1,1-trifluoropropan-2-ol 
• 86884-21-1 rac-4,4,4-trifluoro-3-hydroxybutanoic acid 
• 57165-84-1 1-amino-3-hydroxy-4,4,4-trifluorobutane 

Relevant academic research and scientific papers

CONDENSED HETEROCYCLES AS BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1 Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

HOT MELT EXTRUDED SOLID DISPERSIONS CONTAINING A BCL2 INHIBITOR

A pro-apoptotic solid dispersion comprises, a Bcl -2 family protein inhibitory compound of Formula A as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier, and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of Formula A, the water-soluble polymeric carrier, and the surfactant to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier, and the surfactant and having the compound dispersed in essentially non-crystalline form therein. The solid dispersion is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl -2 family proteins, for example cancer or an immune or autoimmune disease.

BCL-2 INHIBITORS

The disclosure includes compounds of Formula (A), (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, and R11, h, j, m, n, k, v, s, g, V, W, L, Z1, Q1, Q2, Q3, Q4, Q5, Q6, and Q7, are defined herein. Also disclosed is a method for treating a neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

CONDENSED HETEROCYCLIC DERIVATIVES AS BCL-2 INHIBITORS FOR THE TREATMENT OF NEOPLASTIC DISEASES

The disclosure includes compounds of Formula (A) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, and R12, j, k, m, n, Y, W, W1, W2, W3, V, L, Z1, Q1, Q2, Q3, and Q4, are defined herein. Also disclosed is a method for treatinga neoplastic disease, an autoimmune disease, or a neorodegenerative disease with these compounds.

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

Novel indazoles for the treatment and prophylaxis of respiratory syncytial virus infection

The invention provides novel compounds having the general formula: wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.

NOVEL INDAZOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION

The invention provides novel compounds having the general formula: formula (I) wherein R1, R2, R3, R4, R5, R7, A1, A2 and A3 are as described herein, compositions including the compounds and methods of using the compounds.